Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Alphatec Holdings, Inc. ATEC

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$764.2M
▲ 25.0% YoY
$-143.4M
$2.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Alphatec Holdings, Inc. designs, develops, and advances technology for the surgical treatment of spine disorders, and is headquartered in Carlsbad, California. Its biologics offerings include allograft options such as 3D ProFuse Osteoconductive Bioscaffold and a family of AlphaGRAFT products. It invested in new headquarters and opened a distribution facility in Memphis, Tennessee to support its expanding footprint. As of December 31, 2025, it had 913 employees worldwide, with approximately 706 located in the United States and 207 located outside the United States. It was incorporated as a Delaware corporation in March 2005.

Written from the business description in Alphatec Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 764.2M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 764.2 · Net income -143.4
300M600M-100M-200M
2009201220152018202120242025
Compound annual growth
+29.6%
+39.5%
+19.0%
+10.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +39.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−19 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -10.7% · Net -18.8%
-50%-100%
200920172025
ROE
FY2021 · ROE -135.9%
-50%-100%-150%
200920172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -14%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 2.8
-100M-200M
200920172025
Net buybacks $M Dividends $M
FY2021 · Dividends · · Net buybacks -106.8
-50M-100M
2021

Total assetsUSD 791.2M
EquityUSD 12.4M
CashUSD 160.8M
Gross debtUSD 565.9M
Net debtUSD 405.1M
Current ratio2.06×

Net debt stands at 3260% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ATEC, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.80.60.50.40.20.10.10.10.10.10.10.20.20.20.20.20.1
Operating income $B−0.1−0.1−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.20.0−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.20.0−0.00.0−0.00.00.0
Income tax $B−0.00.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.00.0
Net income $B−0.1−0.2−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.2−0.0−0.1−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.1−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0
EPS, diluted $−0.96−1.13−1.54−1.46−1.49−1.18−1.09−1.20−1.08−3.49−21.53−1.90−0.85−0.17−0.25−0.18−0.27
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %————−135.9−91.1−186.3————−8.0−39.4−6.3−8.7−8.4−17.8
Shares out B0.150.140.140.110.100.080.060.040.020.010.100.100.100.100.090.09◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 3 divergences in 82 reconciliationsAUDITED

Reconciled in 14 of the 17 fiscal years we could check. 3 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures3 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image